Earnings quality
Compare earnings and operating cash flow for earnings quality.
AbbVie Inc.
Ticker ABBV · 🇺🇸 United States · Consolidated US GAAP · amounts in dollars
Filed 2026-02-20 · Period end 2025-12-31
Takeaway
Worth trackingSales and operating profit both moved in a healthier direction.
operating margin is 24.6%; equity ratio is -2.4%.
Sales and operating profit moved together — keep watching margins and whether the trend persists next period.
ActionWorth tracking
OP margin24.6%
Equity ratio-2.4%
Last price—
Trailing P/E—
Look at next
- Compare operating cash flow to reported profit across the last two years.
- Open English IR for management commentary on outlook and capital allocation.
- Overlay peers on Compare before judging relative momentum.
About the company
AbbVie Inc. is a US-listed company with consolidated financial statements filed on SEC EDGAR.
Compare trends
Tel (847) 932-7900 · As of filing date 2026-02-20
Financial statements
Income statement
| Account | FY2024 (ended Dec 31, 2024) | FY2025 (ended Dec 31, 2025) |
|---|---|---|
| Revenue | $56.3B | $61.2B |
| Cost of sales* | $45.6B | $49.1B |
| Gross profit | $10.7B | $12.1B |
| Operating profit | $9.1B | $15.1B |
| Income tax | -$570.0M | $2.4B |
| Net income | $4.3B | $1.8B |
| Basic EPS | 2.40 | 1.02 |
Balance sheet
| Account | FY2024 (ended Dec 31, 2024) | FY2025 (ended Dec 31, 2025) |
|---|---|---|
| Cash & equivalents | $5.5B | $5.2B |
| Current assets | $25.6B | $29.1B |
| Non-current assets* | $109.6B | $104.9B |
| Total assets | $135.2B | $134.0B |
| Current liabilities | $38.7B | $43.3B |
| Non-current liabilities* | — | — |
| Total liabilities | — | — |
| Stockholders’ equity | $3.3B | -$3.3B |
Cash flow statement
| Account | FY2024 (ended Dec 31, 2024) | FY2025 (ended Dec 31, 2025) |
|---|---|---|
| Operating cash flow | $18.8B | $19.0B |
| Investing cash flow | -$20.8B | -$6.6B |
| Financing cash flow | -$5.2B | -$12.7B |
| Cash at end of period | $5.5B | $5.2B |
Five-year trends
Key metrics
| Metric | Trend | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B | |
| Operating profit | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B | |
| Net income | $11.5B | $11.8B | $4.9B | $4.3B | $1.8B | |
| Total assets | $146.5B | $138.8B | $134.7B | $135.2B | $134.0B | |
| Cash & equivalents | $9.7B | $9.2B | $12.8B | $5.5B | $5.2B | |
| Stockholders’ equity | $15.4B | $17.3B | $10.4B | $3.3B | -$3.3B |
How we read these numbers
From the notes
No material one-offs extracted from this filing.
Constructive
Sales and operating profit both moved in a healthier direction.
On the income statement, revenue moved from $56.3B to $61.2B (▲ +8.6%). Operating profit went from $9.1B to $15.1B (▲ +65.0%).
Operating cash flow was $19.0B (prior $18.8B), with cash on the balance sheet at $5.2B versus $5.5B.
Liquidity & leverage
Cash moved from $5.5B to $5.2B; current liabilities $43.3B.
Capital buffer
Stockholders’ equity moved from $3.3B to -$3.3B.
Was this page helpful?
Source: SEC EDGAR 0001551152-26-000008
(AbbVie Inc.), period end 2025-12-31.